Solid tumors typically exploit both immune tolerance and also immune privilege mechanisms to escape recognition by the host immune system. Many billions of dollars are currently invested in hundreds of I/O clinical trials that all focus on countering immune tolerance to the tumor, including checkpoint inhibitors and CAR-T cell therapies. None of these trials addresses immune privilege. EnduRx is an early stage company developing novel peptides that target solid tumors by an entirely new modality that overcomes immune privilege as well as reducing tolerance. The EnduRx peptides target proteins uniquely located on the surface of cells in the tumor microenvironment, including: tumor capillary and lymph vessel endothelial cells, tumor stromal cells, tumor macrophages, as well as cancer cells themselves. Initial mouse studies, both syngeneic and xenograft tumor models, show significant efficacy, including complete cures, without any significant toxicity. Not only does this therapeutic approach show efficacy alone, it is completely different from any other current strategy, and is very likely to show synergies with many currently approved cancer therapies.